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. Cells were collected 2 or 6 hours after addition of sphingosine, as indicated. pAkt/tAkt ratios were generated using NIH ImageJ band densitometries, and are represented as raw ratios so that multiple comparisons can be made. c) PPC1 cells were infected with Ad-AC or Ad-GFP in the presence of the indicated dose of SKI-II. 48 hours after infection, cells were analyzed by western blotting. d) WT, SphK1 KO, and SphK2 KO MEFs were infected with Ad-AC or Ad-GFP at MOI 100. 48 hours after infection, cells were analyzed by western blotting. e) PPC1 cells were transfected with non-targeting (SCR) or SphK1 or SphK2 targeting shRNA vectors. 6 hours after transfection, cells were infected with Ad-GFP or Ad-AC. 48 hours after infection, cells were analyzed by western blotting and qRT-PCR. f) PPC1 cells were transfected with nontargeting (SCR) or SphK1 or Sphk2 targeting siRNA. 6 hours after transfection, cells were infected with Ad-GFP or Ad-AC. 48 hours after infection, cells were analyzed by western blotting and qRT-PCR. PPC1 cells were infected with Ad-GFP or Ad-AC for 48 hours and then treated with 5µM C17-C6-Ceramide for the indicated time and then cells (g) and medium (h) were collected and analyzed for C17-S1P by LC/MS. i-j) WT, SphK1 and SphK2 knockout MEFs were infected with Ad-GFP or Ad-AC. After 48 hours, cells (i) and medium (j) were collected and S1P was analyzed by LC/MS. *p<.05 analyzed by student's t test.
S1PR2 stimulates PI3K to activate Akt
To determine whether AC/S1P-induced Akt activation was mediated by S1PRs, we expressed AC in PPC1 cells in the presence of the S1PR1 antagonist W146 or the S1PR2 antagonist JTE013. While W146 had no impact on reducing AC-induced Akt activation (Fig. 4A ), JTE013 strongly inhibited AC-induced Akt activation (Fig. 4B) . Similarly, AC-induced Akt activation was also prevented by JTE013 in WT MEFs, confirming that this phenomenon is intact in PTEN positive as well as PTEN negative (PPC1) cells (Fig. 4C ). When we transfected PPC1 cells with shRNA sequences against S1PR1, S1PR2, or S1PR3, Ad-AC-induced Akt activation was unaffected in multiple S1PR1 and 3 knockdown cells despite 60-70% reduction in mRNA (Fig. 4D , O-P). Both S1PR2 shRNA sequences greatly reduced Ad-AC- 7 induced Akt activation, confirming a prominent role for S1PR2 signaling in activation of Akt downstream of AC. Because the observation that S1PR2 activates an oncogenic signaling pathway challenges the dogma on the role of S1PR2 in cancer cell signaling, we performed a proliferation experiment and found that the proliferation advantage of AC overexpressing prostate cancer cells is diminished by treatment with JTE013 (Fig. 4E ). Basal S1PR1-3 expression was evaluated in PPC1 and DU145, both of which had predominate S1PR2 mRNA with markedly less S1PR1 and 3 ( Fig. 4J ). Further analysis revealed that S1PR2 mRNA is induced slightly (1.3-2 fold) but significantly upon AC expression (Fig. 4K) . Expression of the other ceramidases was not affected by AC expression, except for a reduction in ACER1 mRNA in PPC1 (Fig. 4L ). S1PRs are GPCRs known to stimulate Akt activation by activating G i -mediated stimulation of PI3K. Pertussis toxin (PTX), which inactivates G i , G 0, and G t , prevented AC-induced Akt activation (Fig. 4F) , and the G i inhibitor NF023 abrogated AC-induced Akt activation (Fig. 4G) , suggesting a role for G proteins, specifically G i , in AC-induced Akt activation. Expressing PTEN in PPC1 cells antagonized AC-induced Akt activation (Fig. 4H) , and the PI3K inhibitor LY294002 effected dose-dependent abrogation of pAkt (Fig. 4I) , supporting an S1PR2, PI3K-dependent mechanism. To test whether exogenous S1P works in the same way on these cell lines, we treated PPC1 and DU145 with 500nM S1P for 2 hours in the presence or absence of JTE013 ( Fig. 4M-N) . JTE013 blocked S1P-induced Akt activation in both cell lines, supporting the findings using AC expression to drive increased S1P signaling. .. . After 48 hours of infection, cells were analyzed by western blotting. c) WT MEFs were infected with Asd-AC or Ad-GFP (MOI 100). After 6 hours, cells were treated with the indicated dose of JTE013. After 48 hours, cells were collected for western blotting. d) PPC1 cells were transfected with non-targeting (SCR) or S1PR1-3 targeting shRNA vectors. 6 hours after transfection, cells were infected with Ad-GFP or Ad-AC. 48 hours after infection, cells were analyzed by western blotting and qRT-PCR. e) DU145 EGFP and AC-EGFP cells were plated at low density in 96 well plates in the presence or absence of 1µM JTE013 and analyzed by MTS assay at the indicated days. Statistical analysis was performed using a oneway ANOVA with Bonferroni correction, *p<.05. PPC1 cells were infected with Ad-AC or Ad-GFP. After 48 hours, cell viability was measured by MTS assay. Prism software was used to calculate the EC50 of each compound (Table 1 ) and the EC50 of Ad-AC infected cells was compared to that of Ad-GFP infected cells to determine the percent change in EC50 of Ad-AC infected cells.
Proliferation in AC overexpressing cells is profoundly sensitive to Akt inhibition.
Akt signaling promotes cancer in numerous ways, including increased cell proliferation. To determine whether AC-induced proliferation is Akt-dependent, we evaluated prostate cancer cell proliferation in the presence of AktX and Perifosine. In DU145-AC-EGFP cells stably expressing AC, we noted significantly more rapid cell proliferation compared to vector control ( Fig 6A) . Treatment with AktX ( Fig. 6A) and Perifosine ( Fig. 6C ) both reduced proliferation in AC-EGFP and EGFP cell lines. However, directly comparing cell number at Day 7 revealed that AktX and Perifosine more strongly inhibited proliferation in AC-EGFP cells (Fig. 6B,D) . EGFP cell proliferation was reduced 30% (AktX) and 52% (Perifosine), whereas AC-EGFP cell proliferation was reduced 52% (AktX) and 91% (Perifosine). The same effect was observed in PPC1 cells infected with Ad-AC, in which AktX inhibited cell proliferation 52%, in contrast with Ad-GFP infected cells, which were only slightly impacted with 9% reduction in cell number compared to untreated (Fig. 6E,F ).
Figure 6:
Proliferation in AC overexpressing cells is profoundly sensitive to Akt inhibition. a, c, e) 500 cells were plated on 96 well plates of DU145 AC-EGFP and EGFP (a and c) or PPC1 cells infected with Ad-GFP or Ad-AC (e). After overnight cell attachment cells were treated with 2.5µM AktX (a, e) or 5µM Perifosine (c). At the indicate day, MTS assay was used to determine relative cell proliferation. b, d, f) OD 490 values at day 7 were compared and used to calculate the percent inhibition in cell proliferation in each cell type by the indicated compound. *p<.05 calculated by the student's t test.
AC-induced Akt signaling promotes soft agar colony formation.
Anchorage independent growth is a hallmark of oncogenic potential. PPC1 cells infected with Ad-AC formed more colonies on soft agar compared to Ad-GFP infected cells (Fig. 7A,C) . Interestingly, while inhibition of Akt signaling with AktX and JTE013, the S1PR2 antagonist did not have an impact on soft agar colony formation in Ad-GFP infected PPC1 cells, Ad-AC infected cells were sensitive to both Akt inhibition and S1PR2 antagonism, consistent with the hypothesis that AC-induced Akt activation is oncogenic. Similarly, when cells were infected with an adenovirus delivering an anti-AC short hairpin, Ad-shASAH1, fewer colonies were formed than when cells were infected with non-targeting shRNA (Fig. 7B,D ). one day prior to plating in 6-well plates in a total volume of 4 ml soft agar. a) 4 hours after plating, 5µM JTE013, 10µM AktX, or vehicle (DMSO) was added in 1 ml complete medium. Colonies, represented in c,d, were counted two weeks after plating.
Aim 2: Test the hypothesis that the activation of Akt due to AC overexpression depends on deficient PTEN activity 13 The relationship between AC and Akt activation was investigated using several approaches. We stably expressed AC in PPC1 and DU145 prostate cancer cell lines and found that high levels of AC increased phosphorylation of Akt at Serine 473 compared to vector control cells, indicating activation (Fig. 8A ). In cells with stable shRNA knockdown of AC, we observed a reduction in basal Akt phosphorylation in both DU145 and PPC1 cells versus vector control (Fig. 8B ). This shows that AC expression correlates with Akt activation in PTEN positive (DU145) and negative (PPC1) cell lines. Figure 8H shows that when we express PTEN in PPC1 cells we significantly reduce AC-induced Akt activation. These observations suggest that while PTEN significantly reduces AC-induced Akt activation, AC can activate Akt in the presence or absence of PTEN. Aim 3: Test the hypothesis that AC overexpression contributes to PCa tumor formation and metastasis.
AC promotes oncogenic features of prostate cancer cells in vitro and in vivo.
We co-infected PPC1 cells with Ad-GFP or Ad-AC and Ad-GFP, Ad-WT-PTEN, or Ad-PTEN-NLS. AC promoted nuclear egress of WT-PTEN, but not NLS-PTEN, which remained confined to the nucleus in all cells ( Fig. 8A-B) . Treatment of cells with 1.5 nM Docetaxel induced apoptosis in cells expressing both WT-PTEN and PTEN-NLS more strongly than cells not expressing PTEN (Fig. 8C) , consistent with the role of PTEN in potentiating apoptotic stimuli. Interestingly, while Ad-AC was able to suppress Docetaxel induced apoptosis in Ad-GFP and Ad-WT-PTEN infected cells, Ad-PTEN-NLS infected cells were not protected from apoptosis by Ad-AC. Moreover, the EC50s of these treatments to Docetaxel were increased by Ad-AC, indicating desensitization or protection from cell death due to Docetaxel, however Ad-PTEN-NLS infected cells had no change in EC50 when AC was expressed (Fig. 8D) . These results suggest that AC is able to protect cells from chemotherapy-induced apoptosis and cell death when it is able to promote nuclear egress of PTEN, but not when nuclear expression of PTEN is enforced. In a study of cell proliferation, Ad-GFP and Ad-WT-PTEN infected cells expressing AC proliferated more rapidly than their Ad-GFP infected controls (Fig. 8E) . Interestingly, while the overall rate of proliferation in WT-PTEN expressing cells was slower, Ad-AC promoted proliferation more robustly (1.84 fold at day 8) compared to cells expressing no PTEN (1.2 fold at day 8), suggesting that while AC can promote 14 proliferation in the presence and absence of PTEN, it exerts a more powerful influence in PTEN expressing cells. Cells expressing PTEN-NLS proliferated the least of all treatments, and Ad-AC provided no advantage in proliferation, further suggesting that the ability of AC to promote proliferation depends upon its ability to promote nuclear egress of PTEN. In a study of the ability of AC to promote tumor engraftment in a xenograft study, we found that AC trended towards promotion of formation of tumors more rapidly in cells expressing GFP (control) or a WT-PTEN construct (p=0.1), but not in cells expressing NLS-PTEN (p=0.7) (Fig. 8F) . treated with a dose course (.01 to 100nM) Docetaxel and analyzed for relative cell viability using MTS assay after a further 48 hours. The EC50 was estimated using Prism 4 software. e) Cells were counted on the indicated day (day 0 being the day of plating). Student's t-test, *p<.05, **p<.01. F) 4x10^6 cells were injected into the flanks of nu/nu mice and observed for 6 weeks for the formation of palpable tumors. 
Conclusions:
We have described a pathway by which AC promotes oncogenic Akt signaling through S1P signaling. Several aspects of this pathway are novel including the tumor promoting function of S1PR2, which is often described as a tumor suppressor. We have also concluded that AC promotes PTEN nuclear export via an Akt-S6K-Crm1 mechanism. This was found to be tumor promoting, as enforced nuclear expression of PTEN prevented AC from promoting resistance to Docetaxel and proliferation of prostate cancer cells. 
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INTRODUCTION
AC has been shown to be overexpressed at the mRNA 1 and protein levels 2 in prostate tumors, and has been shown to mediate proliferation, chemo-and radioresistance, 3, 4 and cell invasion.
5
Despite the important processes mediated by AC, the signaling mechanisms underlying these oncogenic phenotypes have been understudied. AC deacylates ceramide to form sphingosine, which can be phosphorylated by sphingosine kinase (SphK)1 or SphK2 to form sphingosine 1-phosphate (S1P). 6 These bioactive lipids have been shown to mediate numerous physiologic and pathologic processes. Ceramide has a well-studied role in Protein phosphatase 2A (PP2A)-mediated deactivation of Akt. 7 The role of sphingosine in regulating Akt is equivocal, with reports of sphingosine-induced Akt activation 8 and deactivation. 9 On the other hand, S1P has been convincingly shown to activate Akt downstream of its G proteincoupled receptors (GPCRs). A number of studies ascribe oncogenic roles to S1PR1 and 3, both of which activate Akt through G i -mediated stimulation of PI3K.
10 S1PR3 also transactivates platelet-derived growth factor receptors (PDGFR) to directly stimulate PI3K. 11, 12 In contrast, S1PR2 is thought to primarily couple to G 12/13 to mediate Rac/Rho-dependent inhibition of cell migration, and through Rho-mediated PTEN (phosphatase and tensin homolog) activation, antagonize Akt activation. 13 However, S1PR2 couples to G i , G 12/13 and G q , and thus may mediate a diverse set of signals. 14 The present study uncovers an important oncogenic signal elicited by AC. We show that AC promotes activation of Akt through SphK1-generated S1P. Interestingly, this signal depends on S1PR2-mediated stimulation of PI3K, challenging the dogma that S1PR2 is tumor-suppressive. AC overexpression confers resistance to nontargeted chemotherapies; however, the oncogenic phenotypes of AC-overexpressing cells are uniquely sensitive to Akt inhibition. This set of observations has immediate clinical implication, as the success of nascent PI3K/Akt inhibitors is likely to depend on determining which tumors are susceptible to interdiction of this pathway, as we here suggest AC-overexpressing prostate tumors may be.
RESULTS
AC and phosphorylation of Akt correlate in prostate adenocarcinoma
Our previous studies have demonstrated that most prostate tumors overexpress AC, compared with benign prostate tissue. 15 As Akt activation is a common feature of many tumors, including prostate, we sought to determine whether there was a relationship between AC expression and Akt activation in the progression to prostate adenocarcinoma. Using a tissue microarray made up of prostate adenocarcinoma and patientmatched benign adjacent biopsy cores from 27 prostate cancer patients, we determined that the 22 patients whose tumor AC immunohistochemistry staining was elevated compared with their benign AC score ( Figure 1a) ; 12 had the same trend in pAkt staining (Figure 1b) . Conversely, none of the five patients whose tumor AC staining was not elevated compared with their benign tissue ( Figure 1c ) had increased pAkt staining (Figure 1d ). Analysis of these data with Fisher's exact test demonstrates that pAkt elevation from benign to tumor is contingent on AC elevation, with a P-value of 0.0307. In a further analysis of 56 prostate tumors immunostained for AC and pAkt, we found that tumors which scored high (above 2.5) for AC also had elevated pAkt scoring compared with AC-low (below 1.5) tumors (Figure 1e ).
AC activates Akt
The relationship between AC and Akt activation was investigated using several approaches. We stably expressed AC in PPC1 and DU145 prostate cancer cell lines and found that high levels of AC Supplementary Figure 1E ). We observed activation of the mammalian target of rapamycin (mTOR) pathway (p-mTOR and p-p70S6K), as well as inhibition of GSK-3beta, which is involved in regulation of cell proliferation and metabolism.
16
SphK1 mediates AC-induced Akt activation The bioactive lipids ceramide, sphingosine and S1P have all been linked to the regulation of Akt. We observed no change in total cell ceramide in Ad-AC-infected PPC1 cells compared with Ad-GFP (Figure 3a) , though species-specific alterations were observed (data not shown). Sphingosine and S1P were significantly elevated in Ad-AC-infected cells (Figure 3a) . In order to measure secreted S1P, we treated Ad-AC/GFP-infected PPC1 cells with C17-C6 ceramide, finding significant C17-S1P increase in the cells (Supplementary Figure 2A) and medium (Supplementary Figure 2B) . Treatment of cells with exogenous sphingosine did not activate Akt, rather decreasing pAkt moderately after 6 h of treatment ( Figure 3b ). Addition of the dual-isoform sphingosine kinase inhibitor SKI-II decreased Akt activation at 6 h, and did not augment Akt activation alone or in combination with sphingosine ( Figure 3b S1PR2 stimulates PI3K to activate Akt To determine whether AC/S1P-induced Akt activation was mediated by S1PRs, we expressed AC in PPC1 cells in the presence of the S1PR1 antagonist W146, or the S1PR2 antagonist JTE013. Whereas W146 had no impact on reducing AC-induced Akt activation ( Both S1PR2 shRNA sequences greatly reduced Ad-AC-induced Akt activation, confirming a prominent role for S1PR2 signaling in the activation of Akt downstream of AC. As the observation that S1PR2 activates an oncogenic signaling pathway challenges the dogma on the role of S1PR2 in cancer cell signaling, we performed a proliferation experiment and found that the proliferation advantage of AC-overexpressing prostate cancer cells is diminished by treatment with JTE013 ( Figure 4e ). Basal S1PR1-3 expression was evaluated in PPC1 and DU145, both of which Figure 1P ), supporting an S1PR2, PI3K-dependent mechanism. To test whether exogenous S1P works in the same way on these cell lines, we treated PPC1 and DU145 with 500 nM S1P for 2 h in the presence or absence of JTE013 (Supplementary Figure 5 ). JTE013 blocked S1P-induced Akt activation in both cell lines, supporting the findings using AC expression to drive increased S1P signaling.
AC promotes chemotherapy resistance, but confers sensitivity to Akt inhibition Cytotoxic chemotherapy depends, in part, on ceramide accumulation to cause cell death. [17] [18] [19] PPC1 cells were subjected to a wide dose range of the cytotoxic chemotherapeutic agents Docetaxel, Gemcitabine and 5 0 -Fluorouracil. PPC1 cells infected with Ad-AC were found to be less sensitive to all the three compounds (Docetaxel: 413%, Gemcitabine: 55% and 5 0 -Fluorouracil: 96% less sensitive), reflected by an increased EC50 ( Figure 5 , Table 1 ). Conversely, AC-overexpressing cells were more sensitive to inhibition of Akt with Akt inhibitor X (AktX), Perifosine or MK2206, with AC-expressing cells being B30-40% more sensitive than Ad-GFP-infected cells.
Proliferation in AC-overexpressing cells is profoundly sensitive to Akt inhibition Akt signaling promotes cancer in numerous ways, including increased cell proliferation. To determine whether AC-induced proliferation is Akt-dependent, we evaluated prostate cancer cell proliferation in the presence of AktX and Perifosine. In DU145-AC-EGFP cells stably expressing AC, we noted significantly more rapid cell proliferation compared with the vector control (Figure 6a ). Treatment with AktX ( Figure 6a ) and Perifosine (Figure 6c ) both reduced proliferation in AC-EGFP and EGFP cell lines. However, directly comparing cell number on day 7 revealed that AktX and Perifosine more strongly inhibited proliferation in AC-EGFP cells (Figures 6b and d) . EGFP cell proliferation was reduced 30% (AktX) and 52% (Perifosine), whereas AC-EGFP cell proliferation was reduced 52% (AktX) and 91% (Perifosine). The same effect was observed in PPC1 cells infected with Ad-AC, in which AktX inhibited cell proliferation 52%, in contrast to Ad-GFP-infected cells, which had no significant reduction in cell number compared with untreated cells (Figures 6e and f) .
AC-induced Akt signaling promotes soft agar-colony formation Anchorage-independent growth is a hallmark of oncogenic potential. PPC1 cells infected with Ad-AC formed more colonies on soft agar compared with Ad-GFP-infected cells (Figures 7a  and c) . Interestingly, while inhibition of Akt signaling with AktX and JTE013, the S1PR2 antagonist did not have an impact on soft agar-colony formation in Ad-GFP-infected PPC1 cells, Ad-ACinfected cells were sensitive to both Akt inhibition and S1PR2 antagonism, consistent with the hypothesis that AC-induced Akt activation is oncogenic. Similarly, when cells were infected with an adenovirus delivering an anti-AC short hairpin, Ad-shASAH1, fewer colonies were formed than when cells were infected with nontargeting shRNA (Figures 7b and d) .
DISCUSSION
AC occupies a powerful position in the balance between ceramide, sphingosine and S1P. As AC is frequently overexpressed in prostate cancer and multiple other malignancies, 15, 20, 21 understanding the dominant downstream signaling consequences of the impact of AC on the ceramide-sphingosine-S1P balance is of great interest. AC expression did not reduce total ceramide, as one might predict; however, species-specific alterations were prominent, particularly reduced C16 ceramide and increased C24 and C24:1 (data not shown). The lack of impact on total ceramide diminished the likelihood that alterations in ceramide-mediated PP2A signaling were responsible for increased Akt activation. Literature on the direct impact of sphingosine on Akt activation is sparse. One report demonstrated in hepatoma cells that exogenous sphingosine promoted apoptosis by decreasing serum-stimulated Akt activation. 22 This is consistent with our observation of exogenous sphingosine decreasing pAkt; however, we cannot conclude whether this is a direct role for sphingosine, as it is a substrate of both SphKs and ceramide synthases. Of interest, AC was shown to drive sphingosine-mediated activation of Akt in alveolar macrophages. 8 Several observations in this study pointed to a direct functional role for sphingosine. However, AC-mediated Figure 5 . AC promotes chemotherapy resistance, but confers sensitivity to Akt inhibition. (a) PPC1 cells infected 24 h prior with Ad-GFP, or Ad-AC were treated with various doses of the indicated compounds. After 48 h, cell viability was measured by MTS assay. Prism software was used to calculate the EC50 of each compound (Table 1 ) and the EC50 of Ad-AC-infected cells was compared with that of Ad-GFP-infected cells to determine the percent change in EC50 of Ad-AC-infected cells. 
Acid ceramidase activates oncogenic Akt signaling TH Beckham et al
Akt signaling was not studied in the context of genetic manipulation or inhibition of SphK, which would have provided strength to the authors' conclusions. In the present study, no role for sphingosine in activating Akt could be demonstrated.
Moreover, it appears that treatment with sphingosine caused deactivation of Akt. One explanation for this is feedback inhibition of AC by exogenous sphingosine, which would lead not only to a reduction of S1P, but also an increase in ceramide, whose role in PP2A-dependent deactivation of Akt is well studied. Salvage generation of ceramide by ceramide synthases could also account for the deactivation of Akt upon addition of exogenous sphingosine. 23 Our data implicate S1P in mediating activation of Akt in the context of AC expression. The vast majority of S1P-mediated phenomena have been attributed to the signaling of its five GPCRs, S1PR1-5. S1PR 4 and 5 are relatively restricted in their expression to the immune system (S1PR4) and the nervous system (S1PR5).
24 S1PR1-3 are ubiquitously expressed, and have numerous roles in diverse phenomena. S1P is characterized to mediate G i stimulation of PI3K, and thereby cause activation of Akt as well as MAPK signaling. These effects have been associated with S1PR1 and, to a lesser degree, with S1PR3, and both receptors have been shown to enhance cell proliferation and migration through Rac activation. [25] [26] [27] [28] In contrast, S1PR2 is thought to predominantly couple with G 12/13 , 24, 29 and thereby antagonize Akt activation by Rho-mediated recruitment of PTEN to the cell membrane. 13 This effect, coupled with its suppression of Rac activity, has resulted in S1P2 being designated as an antimigratory, antiproliferative receptor, which largely opposes the oncogenic signaling of S1PR1 and 3. The present study breaks this dogma by showing that S1PR2 can activate oncogenic Akt signaling in prostate cancer. It is important to note that S1PR2 couples to G i , G 12/13 and G q , with effects of G 12/ 13 predominating in many functional assays. In our study, interdiction of G i signaling substantially reduced AC-induced Akt activation, suggesting that S1PR2 has adopted a G i -dominant downstream signal. Interestingly, the prostate cancer cell lines studied here had far more abundant S1PR2 mRNA than S1PR1 or 3, which may explain why inhibition of S1PR2 had an strong impact on cell signaling and phenotype, however it does not explain why a typically tumor-suppressive receptor now signals to activate Akt. One hypothesis is that S1PR2 is initially upregulated in response to AC overexpression in neoplastic tissues as a means to suppress the oncogenic effects of AC. In the hyperselective tumor environment, cancer cells may evolve to favor G i signaling through S1PR2, compounding the oncogenic insult of AC by further increasing the impact of the downstream metabolite S1P. In support of this, we found that primary prostate epithelial cells had equal expression of S1PR1-3 (data not shown), suggesting that receptor expression is altered at some point during malignant transformation, although we did not observe AC-induced upregulation of S1PR2 in primary cells.
Our study clearly identifies a role for SphK1 in mediating ACinduced Akt activation, with knockout or knockdown of SphK2 having little or no effect. We believe that this may be due to the cellular localizations of the different SphK isoforms. SphK1 has been found to be primarily cytoplasmic or associated with the plasma membrane, whereas SphK2 is largely located in the nucleus or endoplasmic reticulum. 30 As AC resides in the lysosome, thus producing sphingosine primarily in this compartment, it may be that SphK1 has preferential or exclusive access to lysosomal sphingosine. We found that SphK2 KO MEFs had an increase in S1P equivalent to WT MEFs when we overexpressed AC, however SphK1 KO MEFs had no increase in S1P, consistent with this hypothesis.
The observations in this study that AC promotes resistance to cytotoxic chemotherapies but sensitivity to agents that target Akt demonstrate important differences of the diverse functions mediated by AC. An exceedingly common and critical event in cell death in response to nonspecific stressors like radiation and chemotherapy is the accumulation of ceramide, which activates apoptosis through well-characterized mechanisms. 19, 31 The efficacy of cytotoxic chemotherapies in this and previous studies have been shown to be lessened by expression of AC, presumably by dampening the accumulation of ceramide and thus downstream apoptotic signals. 3 In contrast, targeted inhibition of Akt proves especially effective in cells overexpressing AC, indicating that AC-overexpressing cancer cells, and thus potentially AC-overexpressing tumors, are reliant on oncogenic Akt activation through the pathway defined in this study for their oncogenic phenotypes. Chemotherapy for hormone-refractory prostate cancer is currently limited to Docetaxel, which provides minimal benefit. 32 Biopsy-based diagnostic methods could be readily adapted for evaluation of AC expression and Akt activation, potentially informing treatment decisions in the near future as PI3K and Akt inhibitors enter clinical use. Thus, while AC contributes to death resistance in the context of diverse cell stressors such as radiation and chemotherapy by attenuating ceramide accumulation, the identification in this study of AC-mediated Akt activation provides critical insight into specific susceptibilities downstream of AC that could inform future clinical decisions.
Akt signaling promotes proliferation indirectly by activating the mTOR pathway that controls translation of peptides necessary for cell growth, and directly by phosphorylating multiple cyclindependent kinase inhibitors. 33 Our study of the functional consequences of AC-induced Akt signaling reveals three important observations: (1) AC-expressing cells proliferate more rapidly, (2) AC promotes soft agar-colony formation and (3) these oncogenic phenotypes are profoundly sensitive to Akt inhibition. That AC promotes cell proliferation is not surprising, given the signaling mechanism outlined in this study-Akt phosphorylates Wee1 and Myt1 both of which promote mitotic entry by activating cdc2, [34] [35] [36] and Akt directly inactivates the cyclin-dependent kinase inhibitor p27kip1 whose inactivation allows transition from G1/S. 37 More interesting is the finding that AC-overexpressing cells are more sensitive to Akt inhibition with regards to these functional assays than are controls cells. This indicates that ACoverexpressing cells not only rely heavily on Akt signaling for the growth advantages incurred by increased AC signaling, but also for their baseline cell proliferation and tumor formation properties, on the whole suggesting that AC expression causes Akt signaling pathway addiction.
The importance of the pathway outlined in this study is made clear by our tissue microarray studies of human prostate cancer patients. Our ability to study the pattern of expression of AC and pAkt in prostate tumors, and patient-matched benign tissue was critical in understanding whether a statistical relationship existed between AC and pAkt. Simply put, due to the numerous factors that contribute to Akt activation, a prohibitively large sample size would have been required to demonstrate a direct correlation between AC level and phosphorylation of Akt. Instead, we were able to show that when a patient's tumor had more AC than his benign tissue, pAkt tended to increase as well. In patients whose AC did not increase in their tumors, pAkt was not elevated. Analyzing these tissues in a contingency table revealed that a statistically meaningful relationship does exist between AC and pAkt in the benign to adenocarcinoma progression of human prostate tissue. In an analysis of 56 patients' tumors, grouping AC immunohistochemistry score into low-, middle-and high-intensity staining groups revealed that pAkt scores were significantly higher in the AC-high versus AC-low groups, providing more evidence that AC-induced Akt activation is a relevant process in human prostate cancer.
In summary, the present study uncovers a mechanistic basis for oncogenic processes mediated by AC. Cancer cells 
Preparation of tumor tissue microarray
Twenty-seven formalin-fixed paraffin-embedded prostate carcinomas were obtained from the Hollings Cancer Center Tissue Biorepository (Medical University of South Carolina). Tissues were obtained in accordance with an Institutional Review Board approved protocol (no. 426). Three tissue cores were sampled from each tumor, and one core was sampled from adjacent normal tissue. Four-micrometer sections of the tissue microarray were cut and processed for immunohistochemistry. Furthermore, human prostate tissues from the Eastern Virginia Medical School, assembled as described, 38 were immunostained as described below.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were deparaffinized in xylene, rehydrated in alcohol and processed for pretreatment as follows: the sections were incubated with target retrieval solution (Dako, Glostrup, Denmark) in a steamer (Rival, Mill Valley, CA, USA) for 45 min, and then 3% hydrogen peroxide solution for 10 min and protein block (Dako) for 20 min at room temperature. Primary antibody incubation overnight in a humid chamber at 4 1C, followed by biotinylated secondary antibody (Vector, Burlingame, CA, USA) for 30 min and ABC reagent (Vector) for 30 min. Immunocomplexes of horseradish peroxidase were visualized by DAB (Dako) reaction, and sections were counterstained with hematoxylin before mounting. Immunoreactivity was scored using a semiquantitative system, combining intensity of staining (0-3) and percentage of cells staining positive (0-3).
Adenovirus infection AC complementary DNA was purchased from Origene (Rockville, MD, USA) and Ad-AC (adenovirus expressing AC and GFP), and Ad-GFP were developed by Vector Biolabs (Philadelphia, PA, USA). Ad-PTEN was purchased from Vector Biolabs. The short-hairpin sequence (5 0 -CCGGGCTGTTATTGACAGCGATATACTGAGTATATCGCTGT CAATAACAGCTTTTT-3 0 ) obtained from Open Biosystems was validated and developed into an adenoviral delivery vector (Ad-shAC) by Vector Biolabs. A total of 2 Â 10 5 cells were infected in suspension in growth medium and plated on 35-mm dishes. Multiplicity of infection was 50, unless stated otherwise in the figure legend. After overnight attachment, infection was verified by fluorescent microscopy, and the medium was replaced to contain the indicated treatments. For infections following si/shRNA transfection, medium was replaced 24 h after transfection to contain the indicated adenovirus.
Transfections
Dharmacon siGENOME SMART POOL siRNA against SphK1 and SphK2 were purchased from Thermo Fisher, and nontargeting siRNA was purchased from Qiagen (Valencia, CA, USA). siRNA transfections were performed using Oligofectamine (Qiagen) according to the manufacturer's instructions. The following MISSION shRNA sequences were obtained from Sigma Aldrich encoded in pLKO.1 vectors.
These were transfected using Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions.
qRT-PCR si/shRNA knockdown validation was carried out by isolation of RNA using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA) and complementary DNA synthesis using the Bio-Rad (Hercules, CA, USA) iScript complementary DNA synthesis kit, according to the manufacturer's instructions. qRT-PCR was performed by using iCycler iQ real-time PCR detection system (Bio-Rad) using annealing temperature 58 1C and the following primers: Sphk1: forward-5 0 -TGAGCAGGTCACCAATGAAG-3 0 ; reverse-5 0 -TGTGCAGA GACAGCAGGTTC-3 Technologies, Danvers, MA, USA), AC (BD Transduction no. 612302), S1P1 (H-60, Santa Cruz Biotechnology, Santa Cruz, CA, USA), S1P2 (6E8.1, Millipore, Billerica, MA, USA) and S1P3 (no. PA5-28762, Pierce, Rockford, IL, USA). Band densitometries were quantified using NIH ImageJ software (Bethesda, MD, USA). Unless otherwise stated, pAkt/tAkt ratios are represented normalized to the reference (set at 1.00) to allow rapid evaluation of increases or decreases from control. Western blots are representative of a minimum of three independent experiments.
Cell viability assays
A total of 5000 cells per well were infected with Ad-AC or Ad-GFP and plated in 96-well plates. After overnight attachment, medium containing the indicated compound was added. For each compound tested, a broad dose range was selected encompassing doses effecting little to complete cell death. After 48 h, the Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI, USA) was used to approximate the number of viable cells. Prism v4 (GraphPad, La Jolla, CA, USA) was used to determine the EC50 of the various compounds.
Proliferation
A total of 500 cells were plated per well in 96-well plates. After overnight attachment, medium containing the indicated compound was added to the indicated final concentration. On the indicated day (day 1 being the day after plating), the Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) was used to approximate the number of viable cells. All readings were performed 1 h after addition of assay reagent.
Soft agar-colony-formation assay
A base layer composed of 2 ml 0.5% agar, 10% serum and 1 Â RPMI was prepared in six-well plates. A top layer was prepared to a final composition of 0.35% agar, 10% serum and 1 Â RPMI, with 2500 cells per 2 ml. This layer was prepared at 40 1C and plated on top of the base layer. After 4 h at 37 1C, 1 ml complete medium containing the indicated compound was carefully added to the top of each well. In 2 weeks, colony formation was analyzed by counting the number of colonies per Â 100 microscope field. Five fields were counted for each well, and the average of three wells was used to generate data.
Sphingolipid analysis
Ceramide species, sphingosine and S1P from cell pellets were collected and analyzed with LC-MS/MS by the Lipidomics Shared Resource, MUSC, as previously described. 4 
Statistical analysis
Independent experiments were performed a minimum of three times. Statistical analyses on experiments performed in triplicate were performed by unpaired one-tailed Student's t-test, one-way analysis of variance with Bonferroni correction using Prism (version 4.0) from GraphPad, or Fisher's exact test. *Po0.05 was considered significant.
Introduction
PTEN is a critically important tumor suppressor classically known to antagonize oncogenic PI3K/Akt signaling by dephosphorylating the lipid product of PI3K, PIP 3,4,5 , thereby antagonizing pleckstrin homology domain dependent recruitment of Akt and its activating kinase PDK1 to the cell membrane [1, 2] . This function, while undoubtedly a key factor in PTEN-mediated tumor suppression, is by no means the only described role for PTEN with interest in recent years focusing on the role of PTEN within the nucleus. Nuclear PTEN is now known to serve lipid-phosphatase-independent functions in regulating the cell cycle by promoting acetylation of p53 and upregulating RAD51 in response to DNA damage [3] , and by mediating APC/C tumor suppression by promoting association with the adaptor CDH1 [4] . Besides these molecular functions, nuclear PTEN has been observationally linked to tumor suppression. Histological analysis of PTEN has shown that nuclear PTEN in tumor tissue was a favorable prognostic indicator and correlated with a lower tumor proliferation index in melanoma and colon cancer tissues [5, 6] . Interestingly, the most frequent mutation in the hamartomarous condition Cowden Syndrome, in which patients inherit a mutant PTEN allele and are susceptible to cancer, is Lysine289. This mutant form retains its phosphatase activity, but is not imported into the nucleus, providing strong suggestive evidence that nuclear PTEN is important in suppression of neoplasia [7, 8] .
Several studies describe mechanisms that mediate import of PTEN into the nucleus including active import based on multiple cryptic nuclear localization-signal-like sequences, mutation of which abrogated RAN-mediated [9] or Major Vault Protein-mediated [10, 11] nuclear accumulation of PTEN; PTEN C-terminus phosphorylation [12] ; and monoubiquitination [7] . In contrast, little is known about active mechanisms of export of PTEN from the nucleus. One report by Liu, et al, showed that PTEN is exported from the nucleus at the G1/S transition through Akt-mediated activation of S6K [13] . They showed a direct interaction of PTEN with S6K and suggested this is mediated by the master nuclear export protein Crm1.
Here we report Crm1-dependent export of nuclear PTEN in response to sphingosine 1-phosphate (S1P) signaling. We found that expression of acid ceramidase (AC) in prostate cancer cells promoted a loss of nuclear PTEN. Following our recent study outlining AC-mediated Akt activation [14] , we determined that AC-induced Akt activation promoted nuclear export of PTEN. Furthermore, we show that S1P strongly promotes formation of a complex between PTEN and Crm1, and that inhibition of Crm1 with Leptomycin B prevents AC/ S1P-mediated export of nuclear PTEN. Interestingly, while AC was capable of promoting cell proliferation and resistance to Docetaxel in cells expressing wild type PTEN, it was not able to do so in cells expressing PTEN-NLS (wild type PTEN with an N-terminal nuclear localization signal attached), suggesting that the oncogenic properties of AC in prostate cancer involve its ability to regulate the level of PTEN in nucleus. Because most prostate cancers overexpress AC, we report a disease-relevant active mechanism of AC-mediated nuclear PTEN insufficiency promoting prostate cancer.
Materials and Methods
Cell lines and culture
PPC-1 [15] (a kind gift of Dr. Yi Lu, University of Tennessee), 22rv1, and DU145 (ATCC, Manassas, VA) were maintained in RPMI 1640 media supplemented with 10% bovine growth serum and incubated in 5% CO2 at 37°C. DU145-AC-EGFP/ DU145-EGFP have been described [16, 17] .
Reagents
Synthesis of S1P was conducted in the Lipidomics Shared Resource. S1P dry aliquots were prepared by suspension in methanol and lyophilization under a dry nitrogen stream. Aliquots were stored at -80°C until use at which time they were resuspended in PBS to 100µM. Reagents used include: SKI-II, Docetaxel (Thermo, Fisher, Lafayette, CO), LY294002, AktX (Cayman Chemical, Ann Arbor, MI), W146, JTE013 (Tocris, Bristol, UK), Leptomycin B (Sigma, St. Louis, MO), and S6K1 inhibitor DG2 (Millipore, Billerica, MA).
Transfections and plasmid constructs
All plasmid transfections were carried out using Lipofectamine 2000 (Life Technologies) according to manufacturer instructions. The following plasmids were used in this study: Origene PTEN cDNA (SC119965), FLAG-Crm1 [18] (Addgene plasmid #17647), FLAG-PTEN [19] (Addgene plasmid #22231), PTEN-E4 [12] (Addgene plasmid #11171), PTEN-A4 [12] (Addgene plasmid #10753), HA-PTEN-NLS [20] (Addgene plasmid #10933) and HA-PTEN-wt [20] (Addgene plasmid #10750). Wild type PTEN cDNA from Origene was used by Genewiz (La Jolla, CA) as a template for site-directed mutagenesis to mutate the codons encoding Leucine residues at amino acids 334, 336 and 338 to Alanine residues. The resulting construct is referred to as PTEN-AAA.
Preparation of tumor tissue microarray
27 formalin-fixed paraffin-embedded (FFPE) prostate carcinomas were obtained from the Hollings Cancer Center Tissue Biorepository (Medical University of South, Carolina). These tissues were obtained in accordance with an Institutional Review Board approved protocol (426). One-millimeter tissue cylinders were punched from representative tumor areas of a "donor" tissue block and brought into different recipient paraffin blocks each containing 27 individual samples. Three tissue cores were sampled from each tumor, and one core was sampled from patient matched adjacent normal tissue. Fourmicrometer thick sections of the TMA were cut and processed for immunohistochemistry.
Immunohistochemistry
FFPE sections were deparaffinized in xylene, rehydrated in alcohol, and processed for pretreatment as follows: The sections were incubated with target retrieval solution (Dako, Glostrup, Denmark) in a steamer (Rival, CA, USA) for 45 minutes and then 3% hydrogen peroxide solution for 10 minutes and protein block (Dako, Glostrup, Denmark) for 20 minutes at room temperature. Primary antibody incubation overnight in a humid chamber at 4°C followed by biotinylated secondary antibody (Vector, CA, USA) for 30 minutes and ABC reagent (Vector, CA, USA) for 30 minutes. Immunocomplexes of horseradish peroxidase were visualized by DAB (Dako, Glostrup, Denmark) reaction, and sections were counterstained with hematoxylin before mounting. Immunoreactivity was scored using a semiquantitative system combining intensity of staining(0-3) and percentage of cells staining positive(0-3). Separate scores were generated for PTEN staining within the nucleus and the cytoplasm.
Confocal Microscopy
Cells grown on 8-well chamber slides (Becton-Dickinson, Franklin Lakes, NY) were fixed in 3.7% paraformaldehyde, permeabilized in methanol, blocked with 1.5% bovine serum albumin in PBS, and incubated with PTEN primary antibody in 1% BSA/PBS. Bound primary antibodies were detected with Alexa Fluor 555-conjugated goat anti-rabbit secondary antibodies (Invitrogen). Nuclei were stained by incubation with 1:5000 diluted ToPro3-Iodide for 15 minutes. Confocal microscopy was performed using a Leica Laser Scanning Confocal Microscope maintained by the Medical University of South Carolina Hollings Cancer Center Cell and Molecular Imaging Core (1P30 CA138313-01). For each treatment, a minimum of 100 cells were evaluated visually for presence of nuclear PTEN by an evaluator blinded to the treatment group. NIH ImageJ software was used to measure the cytoplasmic and nuclear PTEN stain intensities and the N/C ratios for each treatment were determined. S1P Promotes Nuclear Export of PTEN PLOS ONE | www.plosone.org
Immunoprecipitation
Cells transfected with either FLAG-Crm1 [18] (Addgene plasmid #17647) or FLAG-PTEN [19] (Addgene plasmid #22231) were used for Immunoprecipitation with the Sigma FLAG IP kit in accordance with manufacturer instructions. Briefly, cells were washed twice with ice cold PBS then lysed by gentle shaking with lysis buffer at 4°C for 20 minutes. Cells were scraped and collected into centrifuge tubes, and cellular debris was pelleted by centrifugation at 12,000 g for 12 minutes. Cell lysates were used to suspend anti-FLAG M2 affinity beads. Following overnight rotation at 4°C, beads were pelleted and washed several times before the bound protein was liberated with boiling for 5 minutes in 2X sample buffer. After pelleting the beads, 15µL of the supernatant was analyzed by immunoblotting as described above.
Cellular Fractionation
Nuclear and cytoplasmic fractions were obtained using the REAP method [21] , with slight modification. Briefly, cells were washed twice with ice cold PBS before mechanical disruption of cytoplasmic membranes by tituration (5X with P-1000 pipetor) with .1% NP-40 in PBS. After a 10 second spin in a table top microcentrifuge, the supernantant was reserved as the cytoplasmic fraction. Following an additional brief tituration (2X with P-1000 pipetor) and a 10 second centrifugation, the supernatant was removed and the pellet was resuspended in 30µL RIPA buffer. After 30 minutes of incubation on ice with aggressive vortexing every 10 minutes, nuclear debris was removed by centrifuging at 20,000 x g for 20 minutes. The supernatant is the nuclear fraction.
Adenovirus infection
AC cDNA was purchased from Origene (Rockville, MD) and Ad-AC (adenovirus expressing AC and GFP) and Ad-GFP were developed by Vector Biolabs (Philadelphia, PA). Ad-PTEN was purchased from Vector Biolabs. The short hairpin sequence (5'-ccgggctgttattgacagcgatatactgagtatatcgctgtcaataacagcttttt -3') obtained from Open Biosystems (Huntsville, AL) was validated and developed into an adenoviral delivery vector (Ad-shAC) by Vector Biolabs. The HA-PTEN-NLS construct obtained from Addgene was developed into an adenoviral delivery vector by Vector Biolabs by cloning the PTEN-NLS sequence without the HA tag into an adenovirus construct. Cells were infected in suspension with the indicated MOI of the indicated adenovirus in complete medium.
Western blotting
Cell lysates were prepared and analyzed as previously described [22] , using the following antibodies: pAkt (#4060), total-Akt (#4691) p-P70S6K (#9234), P70S6K (#9202), PTEN (#9559), p-PTEN S380(#9551), p-PTEN S380/Thr382/383 (#9554) Histone-H3 (#4499), β-Tubulin (#2128) DYKDDDDK (FLAG) Tag (#2044) (Cell Signaling Technologies, Danvers, MA), AC (BD Transduction #612302), GAPDH (G-9), and Lamin B (C-20) (Santa Cruz, Santa Cruz, CA).
Cell viability assays
5000 cells per well were infected with Ad-AC or Ad-GFP and plated in 96-well plates. After overnight attachment, medium containing the indicated compound was added. Cells were treated with a broad dose range of Docetaxel from 100 nM to .1 nM, doses encompassing effecting little to complete cell death. After 48 hours, the Promega CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) was used to approximate the number of viable cells. Prism v4 was used to determine the EC50 (concentration at which half of the cells are viable).
Propidium Iodide staining
Cells were trypsinized and washed twice with cold PBS prior to suspension in 100µL PBS followed by 3 ml of -20°C 70% EtOH. After a minimum of one hour incubation at 4°C, cells were washed twice with 2 ml PBS and again resuspended in 100µL PBS. Cells were incubated or one hour with RNase A at a final concentration of 500µg/ml. 20µL of stock solution of propidium iodide (1 mg/ml) was added to a final concentration of 50µg/ml and incubated in the dark at 4°C for 30 minutes prior to analysis for DNA content by flow cytometry with software rendering by ModFit LT 4.0 (Verity Software House).
Proliferation
2000 cells were plated per well in 24-well plates. On the indicated day (day 0 being the day after plating), one plate was fixed in 3.7% formalin and stained with crystal violet. Cell number was determined by counting a minimum of 5 randomly selected microscopic fields (10X objective).
Animal studies
For establishment of xenografts, cells were infected at MOI 25 with each of the indicated adenoviruses in suspension at a density of 1x10 6 cells per mL in serum free medium containing 1% BSA for 4 hours prior to preparation for engraftment by suspension in 1:1 RPMI 1640: Matrigel HC admixture (0.08 mL per injection). Pathogen-free four-week-old female Athymic NCr-nu/nu mice were purchased from the NCI, Frederick Cancer Research Center (Frederick, MD, USA). Animals were monitored for formation of palpable tumors weekly. The mice were maintained under standard conditions according to the institutional guidelines for animal care. All animal experiments were approved by the Committee for the Care and Use of Laboratory Animals of Medical University of SC.
Statistical Analysis
Independent experiments were performed a minimum of three times. Statistical analyses on experiments performed in triplicate were performed by unpaired one-tailed student's t test, one way ANOVA with Bonferroni correction using Prism (version 4.0) from GraphPad, or Fisher's Exact Test. *p<0.05 was considered significant. Time to tumor formation was analyzed via Kaplan-Meier methods. Mice that did not develop tumors were censored at 42 days. The log-rank test was used to compare distributions of time to tumor formation across groups for all pairs of groups.
S1P Promotes Nuclear Export of PTEN
Results
Acid ceramidase correlates with loss of nuclear PTEN in prostate adenocarcinoma
Using a tissue microarray (TMA) made up of prostate adenocarcinoma and patient-matched benign adjacent biopsy cores from 27 prostate cancer patients, we determined that in the patients whose tumor AC immunohistochemistry (IHC) staining was elevated compared their benign AC score (benign AC score: .325, adenocarcinoma AC score: 2.55, p<.001) (Figure 1A) , the percentage of PTEN in the nuclei of the specimens (100*nuclear PTEN score/(cytoplasmic + nuclear PTEN score) was decreased in adenocarcinoma tissue (benign nuclear PTEN: 40.9%, adenocarcinoma nuclear PTEN: 6.25%, p<.05) ( Figure 1B) . Conversely, in patients whose tumor AC staining was not elevated compared to their benign tissue ( Figure 1C ) no decrease in the percentage of nuclear PTEN was observed ( Figure 1D ). The AC scores and nuclear PTEN % are displayed in table form ( Figure 1E ).
Acid ceramidase causes S1P-dependent loss of nuclear PTEN
PPC1 cells transfected with wild type PTEN were infected with either Ad-GFP or Ad-AC. Figure S1 is provided as a demonstration of the degree of AC expression that is enforced using our adenoviral transfection approach which can be compared to the degree of AC overexpression found in human prostate tumors in our previous study [23] . Immunofluorescence to visualize PTEN localization revealed that expression of AC significantly reduced the number of cells that had PTEN in the nucleus, but not in the presence of the sphingosine kinase inhibitor SKI-II. Representative cells are shown in Figure 2A , and quantified in Figure 2B . Nuclei from cells infected with Ad-GFP or Ad-AC were isolated and evaluated for nuclear PTEN by western blotting ( Figure 2C ). Nuclear PTEN was reduced in Ad-AC infected cells, but not in the presence of the sphingosine kinase (SphK) inhibitor SKI-II, suggesting that AC promotes a reduction in nuclear PTEN by a SphK-dependent mechanism. Whole cell lysates from this experiment are shown in Figure S2A . In order to maintain consistency throughout the study, we utilized PPC1 cells, which are PTEN null, transfected with PTEN constructs. This allows evaluation of PTEN and PTEN mutant localization without the effects of endogenous PTEN. In order to verify that this phenomenon occurs with endogenous PTEN, key results were confirmed in DU145 cells. Stable ( Figure S3A-B) and transient ( Figure S3C-D) expression of AC promoted reduction in nuclear PTEN that was blocked by SKI-II, similar to the results obtained in transfected PPC1 cells. To determine whether exogenous S1P could mimic the effects of AC expression, we treated cells with 500 or 1000 nM S1P. Treatment of cells with S1P recapitulated this phenomenon in PTEN-transfected PPC1 ( Figure 2D-F, Figure S2B ) as well as in DU145 cells ( Figure S3E-H) , indicating that S1P promotes a reduction in nuclear PTEN in prostate cancer cells.
S1P promotes Akt-dependent loss of nuclear PTEN
Recent studies from our lab have shown that AC causes activation of Akt through S1P receptor 2 (S1PR2) in prostate cancer cells. To determine whether AC-induced Akt activation mediates loss of nuclear PTEN, we expressed AC in PPC1 cells and analyzed changes in PTEN localization using nuclear fractionation ( Figure 3A ) and confocal microscopy ( Figure 3B-C) . Antagonism of S1PR2 with JTE013 abolished AC-mediated nuclear PTEN loss, as did inhibition of Akt with the inhibitor AktX, indicating that AC-induced Akt activation promotes loss of nuclear PTEN. Treatment of cells with exogenous S1P in the presence of JTE013 and AktX demonstrated that S1P, through S1PR2 and activation of Akt, promotes loss of nuclear PTEN (Figure 3D-F) . Inhibition of S1PR2 or Akt prevented S1P-mediated nuclear PTEN loss in DU145 as well ( Figure S4 ).
S1P mediates Crm1-dependent export of nuclear PTEN
To investigate the mechanism of S1P-mediated nuclear loss of PTEN, we used the Crm1 inhibitor Leptomycin B (LMB) to determine whether we were observing a Crm1-dependent PTEN nuclear export. Indeed, LMB abrogated AC-( Figure 4A -C) and S1P-( Figure 4D -F, Figure S5 ) induced nuclear PTEN loss, suggesting that we are observing activation of Crm1-mediated active export of PTEN upon AC expression or S1P stimulation. To determine whether S1P promotes association of PTEN and Crm1, we transfected cells with either FLAG-Crm1 ( Figure 5A ) or FLAG-PTEN ( Figure 5B ) and analyzed FLAG immunoprecipitates. Interestingly, stimulation of cells with S1P significantly promoted PTEN presence in FLAG-Crm1 immunoprecipitates and, reciprocally, Crm1 in FLAG-PTEN immunoprecipitates, suggesting that S1P stimulates formation of a complex between Crm1 and PTEN. Whole cell lysates from this experiment are shown in Figure S6 . PTEN does not have a described nuclear export sequence (NES), however in silico analysis with NetNES1.1 [24] predicts a weak NES ( Figure S7A ). Site directed mutagenesis of three Leucine residues in the predicted NES to Alanine residues (L334A, L336A and L338A) did not impact S1P-mediated nuclear export ( Figure S7B ) or reduce the presence of PTEN in S1P-stimualted Crm1 immunoprecipitates ( Figure S7C ), suggesting that this predicted NES is not functional. We also evaluated whether phosphorylation of the C-terminus of PTEN was involved in S1P-mediated nuclear export of PTEN, as the phosphorylation status of the C-terminus has been reported to be involved with its nuclear localization [9, 25] . Expression of AC did not promote C-terminus phosphorylation of PTEN ( Figure S8A ), and two mutant versions with Alanine or Glutamate substitutions in phosphorylation residues that were identified as regulating localization of PTEN, A4 (S380A, T382A, T383A, S385A) and E4 (S380E, T382E, T383E, S385E) were both found in S1P-stimulated Crm1 immunoprecipitates ( Figure S8B ). PTEN-E4 and PTEN-A4 were PTEN were equivalently exported upon S1P stimulation ( Figure S8C ), thus we concluded that PTEN C-terminus phosphorylation is not involved in AC/S1P induced nuclear export of PTEN. S1P Promotes Nuclear Export of PTEN PLOS ONE | www.plosone.org 
AC and S1P mediate Crm1-dependent export of nuclear PTEN through S6K activation
Previous reports have shown that Akt promotes PTEN nuclear export through Crm1, mediated by a physical interaction with S6K [13] . In keeping with our previous findings that AC, through S1P, promotes activation of Akt and its downstream targets, overexpression of AC ( Figure 5C ) and treatment with exogenous S1P (Figure 5D ) promoted phosphorylation of S6K. To evaluate whether S6K-dependent nuclear export of PTEN was involved in our observations, we used the S6K1 inhibitor S6K1 Inhibitor II (here called S6Ki). The S6K inhibitor prevented S1P-mediated PTEN nuclear egress ( Figure 5E-F) . Moreover, utilization of S6Ki prevented the association of PTEN with Crm1 upon S1P stimulation, as noted by the absence of S1P-stimulated increase in PTEN in FLAG-Crm1 immunoprecipitates in the presence of S6Ki ( Figure 5G ). These findings strongly suggest that AC/S1P promote nuclear egress of PTEN through the formation of an S6K-mediated complex with Crm1, as previously described.
Oncogenic features of AC expressing cells are absent in the presence of nuclear localized PTEN
Nuclear PTEN has been found to promote apoptosis and suppress cell proliferation. Therefore, we set out to determine whether the ability of AC to promote nuclear egress of PTEN was functionally important for these phenotypes. We coinfected PPC1 cells with Ad-GFP or Ad-AC and Ad-GFP, Ad-WT-PTEN, or Ad-PTEN-NLS. AC promoted nuclear egress of WT-PTEN, but not NLS-PTEN, which remained confined to the nucleus in all cells ( Figure S9A ). Moreover, PTEN-NLS and WT-PTEN are expressed at similar levels ( Figure S9B ) Treatment of cells with 1.5 nM Docetaxel induced apoptosis in cells expressing both WT-PTEN and PTEN-NLS more strongly than cells not expressing PTEN (Figure 6A) , consistent with the role of PTEN in potentiating apoptotic stimuli. Interestingly, while Ad-AC was able to suppress Docetaxel induced apoptosis in Ad-GFP and Ad-WT-PTEN infected cells, Ad-PTEN-NLS infected cells were not protected from apoptosis by Ad-AC. Moreover, the EC50s of these treatments to Docetaxel were increased by Ad-AC, indicating desensitization or protection from cell death due to Docetaxel, however Ad-PTEN-NLS infected cells had no change in EC50 when AC was expressed ( Figure 6B ). These results suggest that AC is able to protect cells from chemotherapy-induced apoptosis and cell death when it is able to promote nuclear egress of PTEN, but not when nuclear expression of PTEN is enforced. In a study of cell proliferation, Ad-GFP and Ad-WT-PTEN infected cells expressing AC proliferated more rapidly than their Ad-GFP infected controls ( Figure 6C ). Interestingly, while the overall rate of proliferation in WT-PTEN expressing cells was slower, Ad-AC promoted proliferation more robustly (1.84 fold at day 8) compared to cells expressing no PTEN (1.2 fold at day 8), suggesting that while AC can promote proliferation in the presence and absence of PTEN, it exerts a more powerful influence in PTEN expressing cells. Cells expressing PTEN-NLS proliferated the least of all treatments, and Ad-AC provided no advantage in proliferation, further suggesting that the ability of AC to promote proliferation depends upon its ability to promote nuclear egress of PTEN. In a study of the ability of AC to promote tumor engraftment in a xenograft study, we found that AC trended towards promotion of formation of tumors more rapidly in cells expressing GFP (control) or a WT-PTEN construct (p=0.1), but not in cells expressing NLS-PTEN (p=0.7) ( Figure 6D ).
Discussion
Once thought to be an exclusively cytoplasmic protein, PTEN has been found in the nuclei of numerous cell types. Interestingly, studies in breast tissue [26] , thyroid tissue [27] , and pancreatic tissue [28] have all found that nuclear PTEN is generally found in benign or resting cells but tends to be lost in more aggressive cancer cells. Because PTEN is now well known to be a tumor suppressor in the nucleus in addition to its well-appreciated role in cytoplasmic tumor suppression, determining how PTEN gets in and out of the nucleus is of great interest. A number of studies describe mechanisms of PTEN nuclear import [7, 9, 11, 12] , however very little information is known about export of PTEN from the nuclear compartment. We initially observed that cells overexpressing AC seemed to have a reduced amount of nuclear PTEN compared to controls, which led us to investigate the mechanism behind this observation. Having recently discovered that AC promotes activation of Akt through S1P receptor 2-mediated stimulation of PI3K [14] , we sought to determine whether AC-induced reduction of nuclear PTEN is mediated by S1P-induced activation of Akt. By inhibiting sphingosine kinase, S1PR2, and Akt in AC-overexpressing cells, we found that the previously described pathway of AC-induced Akt activation was indeed necessary for AC to promote nuclear egress of PTEN. The essential role of this pathway was confirmed using S1PR2 and Akt inhibition in cells stimulated with exogenous S1P.
Having found that AC-mediated Akt activation promoted loss of nuclear PTEN, we were interested in determining what mechanisms of PTEN nuclear export might be responsible for the phenomenon we observed. Our mutation of an in silico predicted nuclear export sequence (NES) and multiple Cterminus phosphorylation sites did not support classical direct nuclear export or alteration in PTEN C-terminus phosphorylation as contributory to AC/S1P-mediated nuclear export of PTEN [12] . Alfred Yung's group has found evidence that PTEN moves from the nucleus to the cytoplasm in response to Akt activation through mTOR-mediated activation of S6K [13] . In that study, inhibition of PI3K, mTOR, and S6K1 all prevented export of PTEN. They concluded that this export was dependent on Crm1, as the inhibitor Leptomycin B prevented export of PTEN from the nucleus. Overall, they presented compelling evidence of a negative feedback loop through which activation of Akt is suppressed by recruiting a nuclear reservoir of PTEN into the cytoplasm. Because we observed AC-induced, Akt-dependent PTEN nuclear egress, we sought to determine whether the previously discovered Crm1-mediated S6K dependent export was occurring in our system. Indeed, we found that not only does Leptomycin B suppress AC and S1P mediated export of nuclear PTEN, as found in the Yung study, but also the novel observation that S1P Promotes Nuclear Export of PTEN A) After 24 hours plating, cells were treated with 1.5nM Docetaxel and after a further 48 hours, stained with propidium iodide and analyzed for apoptotic cells using FACS. B) After 24 hour attachment, cells were treated with a dose course (.01 to 100nM) Docetaxel and analyzed for relative cell viability using MTS assay after a further 48 hours. The EC50 was estimated using Prism 4 software. C) Cells were counted on the indicated day (day 0 being the day of plating). Student's t-test, *p<.05, **p<.01. D) 4x106 cells were injected into the flanks of nu/nu mice and observed for 6 weeks. We monitored the mice each week for the formation of palpable tumors and graph the number of mice in the indicated treatment that had established palpable tumor at the indicated day. doi: 10.1371/journal.pone.0076593.g006 S1P Promotes Nuclear Export of PTEN S1P stimulation promotes formation of a physical complex between PTEN and Crm1. Similar to the Yung study, inhibition of S6K prevented export of nuclear PTEN and abolished S1P-mediated formation of the Crm1-PTEN complex, suggesting that the previously described mechanism is active in our observed phenomenon. The Yung study specifically outlined Akt-mediated export of PTEN at the G1/S transition. Our results do not implicate a cell-cycle dependent event as we observed a reduction in nuclear PTEN intensity in 100% of cells following S1P treatment, and synchronization in G1 by serum starvation did not affect the localization of PTEN or the impact of AC/S1P on the percentage of intensity of nuclear PTEN (data not shown). The discrepancy is likely due to the different cell types used between our study and Yung's, in which the majority of the data regarding the G1/S transition was gathered in fibroblasts compared to our study, which uses epithelial prostate carcinoma cells in which derangements in cell cycle processes are severe.
While identifying the mechanism by which AC promoted nuclear loss of PTEN was a chief goal of this study, we were also interested in whether PTEN translocation affects a relevant disease state. AC is overexpressed in the majority of prostate tumors at the mRNA [29] and protein [23] levels, and years of study by our group have shown that AC promotes oncogenic phenotypes in prostate cancer by promoting resistance to chemotherapy [16] and radiotherapy [22] and promoting cell proliferation and xenograft growth [16] . Thus, AC overexpression is a relevant model in which to investigate whether nuclear export of PTEN is an impactful event on the behavior of prostate cancer. To establish this, we evaluated expression of AC and nuclear and cytoplasmic expression of PTEN in a human prostate TMA which contains 27 patient matched adenocarcinoma and benign adjacent tissues, allowing us to evaluate molecular alterations that occur in an individual patient's diseased tissue. In this analysis, we found that in patients whose cancer tissue had elevated AC expression compared to their benign tissue also experienced a loss of nuclear PTEN in the benign to cancer transition. Patients whose tumors did not upregulate AC did not lose nuclear PTEN. This mirrors observations in melanoma, colon cancer, and others in which nuclear PTEN was more prevalent in benign tissue than in cancer [5] , with the added implication that AC promotes nuclear egress of PTEN during the development of human prostate cancer. These observations that nuclear PTEN loss may be a consequence of AC overexpression are interesting as nuclear PTEN loss has been found to be a negative prognostic indicator in multiple cancer types.
Functionally, we investigated two of the processes that nuclear PTEN has been found to mediate: apoptosis and proliferation. While some studies have shown that nuclear PTEN does not mediate apoptosis [30] , nuclear PTEN is known to regulate p53 acetylation [31, 32] and promote apoptosis in response to TNF alpha and doxorubin [9] . To induce apoptosis, we used the standard of care therapy for hormone refractory prostate cancer, Docetaxel, finding that AC expression rescued PPC1 cells expressing wild type PTEN from apoptosis with a concomitant increase in the EC50 of Docetaxel in these cells.
This observation is largely consistent with our previous report that AC expression in DU145 cells, which bear wild type PTEN, promotes resistance to taxanes [16] . In contrast, cells expressing nuclear localized PTEN were not protected from Docetaxel by expression of AC, which promoted no change in percentage of apoptotic cells or EC50. This observation identifies a potential mechanism by which active reduction in nuclear PTEN may promote escape from apoptosis in response to chemotherapy and potentially other therapeutics. The Pandolfi group has recently shown impressive evidence that nuclear PTEN suppresses the APC/C (anaphasepromoting complex/cyclosome), which opposes several cellcycle promoting proteins by promoting their ubiquitin-mediated degradation [4] . This study provides strong mechanistic and functional evidence that nuclear PTEN opposes cell proliferation. Interestingly, expression of AC in cells bearing wild type PTEN promoted cell proliferation 53% more than cells bearing no PTEN, suggesting that while AC promotes cell proliferation in the absence of PTEN, the presence of PTEN allows a more prominent effect, suggesting that the interaction of AC with PTEN is a factor in its ability to promote cell proliferation. It is worth noting that the PTEN-independent promotion of proliferation by AC is not surprising, as Akt has several well-known roles in promoting cell proliferation. In contrast, expressing AC in cells with enforced nuclear expression of PTEN had no impact on cell proliferation, again illustrating that the ability of AC to promote nuclear export of PTEN is an important part of its suppression of oncogenic properties in prostate cancer cells. To test whether the impact of AC on PTEN was important in vivo, we found that while both PTEN-NLS and wild type PTEN suppressed xenoengraftment, AC trended towards promotion of tumor formation only in cells bearing no PTEN or WT-PTEN, although these results were not statistically significant (p=0.1). Consistent with sensitivity to Docetaxel and proliferation, AC was unable to promote tumor formation in cells bearing PTEN-NLS (p=0.7). The functional studies performed in this work present evidence that AC promotes cell proliferation, resistance to therapy, and potentially tumor formation in part through its ability to cause translocation of PTEN out of the nucleus, effectively promoting nuclear insufficiency of PTEN tumor suppression.
Conclusion
In this study, we conclude that the Akt activation caused by AC overexpression promotes nuclear export of PTEN in prostate cancer. This phenomenon is dependent upon S1P-mediated activation of Akt which further activates S6K to promote a complex formation between PTEN and the master nuclear exporter Crm1. In human tissues, we found that upregulation of AC during the benign to tumor progression is accompanied by a loss of PTEN in the nucleus. Functional analysis revealed that the ability of AC to promote nuclear egress of PTEN was important for its promotion of proliferation, resistance to standard chemotherapy, and potentially xenoengraftment. This study provides evidence that AC, which is overexpressed in most prostate cancers, exerts its S1P Promotes Nuclear Export of PTEN oncogenic functions in part through promoting insufficiency of PTEN tumor suppression in the nucleus. Figure S1 . PPC1 cells were infected with Ad-AC at MOI ranging from 0 to 50, or Ad-GFP at MOI 50 and probed for expression of AC. NIH ImageJ was used to measure band densitometries and generate AC/Actin ratios, which were normalized to Ad-GFP MOI 50. 
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